In a session of the International Myeloma Workshop (IMW) today, multiple myeloma experts presented the latest data about the efficacy of Revlimid maintenance therapy and discussed the drug’s potential link to second cancers.

Results from a study conducted by the Cancer and Leukemia Group B (CALGB) showed that Revlimid (lenalidomide) maintenance therapy following stem cell transplantation significantly extends survival of myeloma patients.  Two other studies investigating Revlimid maintenance, the IFM 2005-02 and MM-015 studies, have not yet shown a survival benefit.

All three studies, however, have raised concerns that Revlimid maintenance may increase a myeloma patient’s risk of developing a second cancer.  Interim results presented in December as well as updated results from each of the trials presented today showed that more patients who received Revlimid maintenance reported second cancers as compared to patients who did not receive Revlimid.

The presentations of the trial results were followed by a panel discussion about Revlimid and second cancers.  Many of the panel participants were uncertain whether Revlimid increases the risk of developing a second cancer.

For more information on today’s IMW session on second cancers, see The Myeloma Beacon’s extensive coverage of each of the presentations in the Beacon forums.  The Beacon will also provide more details in a daily update about day three of the workshop.  For more related information, see the Beacon’s previous coverage of the Revlimid controversy.